- No file added yet -

Related Article from Test-Firing Ammunition for Spliceosome Inhibition in Cancer

dataset

posted on 2023-03-31, 17:48 authored by Scott M. Dehm

History

ARTICLE ABSTRACT

E7107 is a derivative of the pladienolide family of natural product spliceosome inhibitors, which targets the U2 small nuclear ribonucleoprotein (snRNP) subunit SF3b. The results of a first-in-human trial with E7107 have been reported, representing an important translational step toward the goal of modulating RNA splicing for cancer therapy. Clin Cancer Res; 19(22); 6064–6. ©2013 AACR.